HIGHLIGHTS
- who: Li An and collaborators from the University of Campania Luigi Vanvitelli, Italy have published the research: Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC, in the Journal: (JOURNAL) of August/27,/2019
- what: The study provides new insights into the efficacy and safety of pralsetinib in elderly patients with RET fusion-positive NSCLC. In the current study, the old patient developed grade 2 hypertension, grade 1 neutropenia, and grade 1 elevated AST with pralsetinib therapy at an initial dose of 400 mg once daily . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.